Skip to content Skip to navigation

Stock Losses

This securities fraud class action lawsuit alleges that KLX, Inc. violated the federal securities law by materially misrepresenting the value of its intangible assets and its goodwill associated with the Company's Energy Services Group, along with its policies and the methodology implemented to calculate goodwill, risk and asset impairment, conduct which ultimately caused significant losses to investors.

This securities class action lawsuit alleges that defendant VimpelCom made false and misleading statements about its business and prospects and also failed to disclose material facts concerning its payment of unlawful bribes in order to secure the company's access to Uzbekistan's telecommunications market and the fact that those actions led to probes and criminal investigations by the SEC, Dutch authorities and the U.S. Department of Justice.

Starz Securities Fraud Class Action

This securities class action lawsuit alleges that Starz failed to disclose several material facts with regard to the business and prospects of the company during the relevant period concerning allegedly illicit practices committed by its officers. As a result, the stock traded at artificially inflated prices, eventually causing the plaintiff to suffer losses once the true facts about the company became apparent.

Terraform securities fraud

This securities lawsuit alleges that the Registration Statement and Prospectus related to an initial public offering (IPO) of TerraForm Global contained materially incorrect or misleading statements and omitted material information that was required by law to be disclosed, ultimately resulting in losses to the plaintiff and prospective class members.

This securities class action alleges that TCP International Holdings failed to disclose material facts relating to the company's chairman and improper personal payments he made relating to the business, did not disclose improper relationships with he had with vendors and misled investors with regard to the company's business operations and future prospects.

This federal securities class action lawsuit is brought against SouFun Holdings, which operates a real estate internet portal in China, for making misleading statements and failing to disclose that: (1) SouFun employees routinely created “fake contracts”; (2) Defendants were aware that SouFun employees routinely created “fake contracts”; and (3) as a result, the Company’s public statements were materially false and misleading and lacked a reasonable basis at all relevant times.

This securities class action lawsuit allege Spectrum Pharmaceuticals overstated the likelihood that the FDA would approve of EVOMELA for treatment of multiple myeloma.

Shareholder sues GNC for securities fraud

This federal securities class action lawsuit is brought against GNC for releasing false material statements and failing to disclose that: (1) GNC unlawfully sold thousands of units of products in Oregon that contained picamilon; and (2) GNC unlawfully sold thousand of units of products in Oregon that contained BMPEA.  The above statements artificially inflated GNC’s stock price inducing the Plaintiffs to purchase its securities.

This federal securities class action lawsuit is brought against BofI Holdings, Inc., a holding company for BofI Federal Bank, a provider of consumer and business banking products through the Internet in the U.S.  BofI’s most significant business is making mortgages to high-net-worth individuals for the purchase of expensive properties through BofI’s Bank of Internet USA brand.  The complaint alleges that throughout the class period: (i) BofI’s internal controls were frequently disregarded; (ii) Bank of Internet’s borrowers included foreign nationals who should have been off-limits under federal anti-money-laundering laws; (iii) many Bank of Internet accounts lacked required tax identification numbers; and (iv) Bank of Internet fired an internal auditor who raised the foregoing issues to management and to federal regulators.

This federal securities class action lawsuit is brought against Zafgen, Inc., a small pharmaceutical company researching and experimenting on the release of a single product – an anti-obesity drug called beloranib, and its CEO, Thomas E. Hughes.  The complaint alleges that defendants fraudulently withheld material information from investors: (1) heavy insider trading in September 2015 due to the thrombotic adverse effects of beloranib; (2) patient death in an ongoing Phase 3 beloranib study not made public by Zafgen’s management; (3) Zafgen only reported 2 cases of thrombotic events and concealed the existence of additional 4 adverse events in prior clinical studies.

Pages